Harper M, Kim J, Pandalai P
J Clin Med. 2022; 11(10).
PMID: 35628966
PMC: 9143396.
DOI: 10.3390/jcm11102840.
Amorim L, Peixoto R
Int Cancer Conf J. 2022; 11(1):2-5.
PMID: 35127313
PMC: 8786986.
DOI: 10.1007/s13691-021-00526-7.
Jurczyk M, Krol M, Midro A, Kurnik-Lucka M, Poniatowski A, Gil K
J Clin Med. 2021; 10(19).
PMID: 34640443
PMC: 8509845.
DOI: 10.3390/jcm10194426.
Harada K, Ferdous T, Ueyama Y
Jpn Dent Sci Rev. 2017; 53(3):61-77.
PMID: 28725297
PMC: 5501734.
DOI: 10.1016/j.jdsr.2016.11.001.
Ma Y, Yang I, Tsai H, Huang C, Juo S, Wang J
DNA Cell Biol. 2013; 33(2):64-72.
PMID: 24283362
PMC: 3929122.
DOI: 10.1089/dna.2013.2161.
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.
Kline C, El-Deiry W
Pharmaceuticals (Basel). 2013; 6(8):988-1038.
PMID: 24276379
PMC: 3817731.
DOI: 10.3390/ph6080988.
Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.
Yi H, Cho H, Cho S, Lee D, Abd El-Aty A, Yoon S
BMC Cancer. 2010; 10:211.
PMID: 20482808
PMC: 2889891.
DOI: 10.1186/1471-2407-10-211.
Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response.
Serafino A, Sinibaldi Vallebona P, Andreola F, Zonfrillo M, Mercuri L, Federici M
BMC Immunol. 2008; 9:17.
PMID: 18423004
PMC: 2374764.
DOI: 10.1186/1471-2172-9-17.
Phase I study of continuous mitomycin-C infusion in concomitant radiochemotherapy of primary inoperable advanced head and neck cancer.
Christiansen H, Hermann R, Hille A, Schmidberger H, Martin A, Nitsche M
J Cancer Res Clin Oncol. 2005; 131(12):815-20.
PMID: 16142489
DOI: 10.1007/s00432-005-0028-x.
Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer.
Park S, Bang S, Cho E, Shin D, Lee J, Lee W
BMC Cancer. 2005; 5:87.
PMID: 16042786
PMC: 1183196.
DOI: 10.1186/1471-2407-5-87.
Complications of hepatic artery infusion: a review of 4580 reported cases.
Barnett K, Malafa M
Int J Gastrointest Cancer. 2003; 30(3):147-60.
PMID: 12540027
DOI: 10.1385/IJGC:30:3:147.
Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).
LoRusso P, Prakash S, Wozniak A, Flaherty L, Zalupski M, Shields A
Invest New Drugs. 2002; 20(1):63-71.
PMID: 12003195
DOI: 10.1023/a:1014430216434.
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.
Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S
Br J Cancer. 2001; 85(7):939-43.
PMID: 11592762
PMC: 2375091.
DOI: 10.1054/bjoc.2001.2031.
Effects of carp and tuna oils on 5-fluorouracil-induced antitumor activity and side effects in sarcoma 180-bearing mice.
Kimura Y, Takaku T, Nakajima S, Okuda H
Lipids. 2001; 36(4):353-9.
PMID: 11383685
DOI: 10.1007/s11745-001-0727-3.
The oral fluorinated pyrimidines.
de Bono J, Twelves C
Invest New Drugs. 2001; 19(1):41-59.
PMID: 11291832
DOI: 10.1023/a:1006404701008.
Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer.
Stremetzne S, Streit M, Kreuser E, Schunack W, Jaehde U
Pharm World Sci. 1999; 21(4):184-9.
PMID: 10483607
DOI: 10.1023/a:1008671129128.
Prevention by chitosan of myelotoxicity, gastrointestinal toxicity and immunocompetent organic toxicity induced by 5-fluorouracil without loss of antitumor activity in mice.
Kimura Y, Okuda H
Jpn J Cancer Res. 1999; 90(7):765-74.
PMID: 10470290
PMC: 5926136.
DOI: 10.1111/j.1349-7006.1999.tb00813.x.
Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.
Poorter R, Bakker P, Veenhof C
Pharm World Sci. 1998; 20(2):45-59.
PMID: 9584337
DOI: 10.1023/a:1008605600414.
Mature results from three large controlled studies with raltitrexed ('Tomudex').
Cunningham D
Br J Cancer. 1998; 77 Suppl 2:15-21.
PMID: 9579851
PMC: 2149726.
DOI: 10.1038/bjc.1998.421.
Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy.
Labianca R, Pessi M, Zamparelli G
Drugs. 1997; 53(4):593-607.
PMID: 9098662
DOI: 10.2165/00003495-199753040-00005.